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Abstract
Introduction: Hemoglobin Q-Iran (a75Asp®His) is an important member of the hemoglobin Q family, molecularly
characterized by the replacement of aspartic acid by histidine. The first report of hemoglobin Q-Iran and the
nomenclature of this hemoglobinopathy dates back to 1970. Iran is known as a country with a high prevalence of
a- and b-thalassemia and different types of hemoglobinopathy. Many of these variants are yet to be identified as
the practice of molecular laboratory techniques is limited in this part of the world. Applying such molecular
methods, we report the first hemoglobin Q-Iran cases in Northern Iran.
Case presentation: An unusual band was detected in an isoelectric focusing test and cellulose acetate
electrophoresis of a sample from a 22-year-old Iranian man from Mazandaran Province. Capillary zone
electrophoresis analysis identified this band as hemoglobin Q. A similar band was also detected in his mother’s
electrophoresis (38 years, Iranian ethnicity). The cases underwent molecular investigation and the presence of a
hemoglobin Q-Iran mutation was confirmed by the amplification refractory mutation system polymerase chain
reaction method. Direct conventional sequencing revealed a single guanine to cytosine missense mutation (c.226G
>C ;GAC >CAC) at codon 75 in the a-globin gene in both cases.
Conclusion: The wide spectrum and high frequency of nondeletional a-globin mutations in Mazandaran Province
is remarkable and seem to differ considerably from what has been found in Mediterranean populations. This short
communication reports the first cases of patients with hemoglobin Q found in that region.
Introduction
Hemoglobin (Hb) Q is a single nucleotide polymorph-
ism occurring in the Hb a-2 chain. Hb Q variants are
recognized by a slow-moving band migrating at a similar
position to Hb S on alkaline pH electrophoresis. This
Hb Q variant has normal solubility [1].
A number of important members of the Hb Q family
share a certain molecular feature-the replacement of
aspartic acid (Asp) by histidine (His) at different posi-
tions in the amino acid chain. These include Hb Q-
Thailand (a74 Asp®His), Q-India (a64 Asp®His) and
Q-Iran (a75 Asp®His). The association of Hb Q-Thai-
land with a-thalassemia is frequently reported and the
majority of patients show moderate red cell microcytosis
[2]. In contrast, there are few reports of any affiliation
of Hb Q-India and Hb Q-Iran with other Hb disorders
and deletions [3].
Computerized simulation of secondary and tertiary
protein structures of these Hb molecules by standard
bioinformatic methods suggest that Hb Q-Iran and Hb
Q-Thailand have one and two extra helices respectively,
whilst Hb Q-India has a protein structure similar to the
normal Hb molecule [4]. In the heterozygous state,
patients with Hb Q-India or Hb Q-Iran do not have the
thalassemia phenotype or any distinctive clinical mani-
festation. Furthermore, these Hb abnormalities do not
affect hematologic features. The replacement of aspartic
acid with histidine is on the surface of the protein struc-
ture and does not affect the protein interchain contacts
and electrical charges of the molecule, and therefore
does not cause any changes in hematologic parameters
and indices [5]. Interestingly, in a unique report of a
homozygous patient with Hb Q-Iran, no clinical symp-
tom was observed [6].
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this hemoglobinopathy dates back to 1970 and the work
of Lorkin et al., introducing the substitution of aspartic
acid by histidine at position a75 (EF4) as the responsible
defect for this hemoglobinopathy [5]. In 2007, Rahimi
and colleagues reported the first incidence of such a
hemoglobinopathy in an Iranian individual [7].
Iran is known as a country with a high prevalence of
a-a n db-thalassemia and different types of hemoglobi-
nopathy. Many of these variants are yet to be identified
as the practice of molecular laboratory techniques is
limited in this part of the world. Applying molecular
methods, we here report the first cases of patients with
Hb Q-Iran in Northern Iran.
Case presentation
A 22-year-old Iranian man originally from the northern
province of Mazandaran, was admitted to Fajr Labora-
tory Center (Sari, Iran) for premarital thalassemia
screening. All evaluated hematologic indices were in the
normal range (Table 1); however, both isoelectric focus-
ing and cellulose acetate electrophoresis techniques
revealed an unusual slow moving electrophoretic band
in the location of Hb Q. A hematological investigation
was then performed for the whole family. His father’s
blood tableau and Hb electrophoretic pattern were com-
pletely normal. His mother was a 38-year-old of Iranian
ethnicity with normal hematologic indices. Her Hb elec-
trophoretic pattern contained a band suspected to be
Hb Q. Further evaluation by automatic capillary zone
electrophoresis (Minicap system, Sebia, France) revealed
an extra peak in the graphs of our two patients, identi-
fied as Hb Q (Table 1). Previous reports of the quantity
of Hb Q-Iran are stated to be 17% to 19% of the total
Hb content. In our study, we found the amount of Hb
Q-Iran to be 19.2% in these heterozygous individuals.
The family was then referred to the Kariminejad-Naj-
mabadi Pathology and Genetics Center for molecular
analysis. Deoxyribonucleic acid (DNA) samples were
obtained from all members of the family and analyzed
for a-globin mutations. The samples were examined by
DNA analysis for the presence of the Hb Q-Iran muta-
tion using the amplification refractory mutation system
polymerase chain reaction method. Automated direct
nucleotide sequencing (ABII377, Applied Biosystems,
Foster City, California, USA) of the amplified a2- and
a1-globin genes was performed to characterize other
nondeletional a-thalassemia determinants. Direct con-
ventional sequencing revealed a single guanine to cyto-
sine missense mutation (c.226G > C; GAC >CAC) at
codon 75 in the a-globin gene in all samples except
from the father (Figure 1). No other a-globin mutation
could be detected by direct nucleotide sequencing.
Despite the normal clinical features of our patients,
laboratory findings led to the identification of a rare Hb
variant, Hb Q-Iran. Hereby, we report a family in the
north of Iran whose members are carriers of the Hb Q-
Iran gene.
Discussion
Iran is a multiethnic country with a vast variation of
thalassemia-causing mutations and there are reports of
hemoglobinopathies from different regions of that coun-
try [8]. The northern (Mazandaran and Gilan) and
southern (Khuzestan) provinces of Iran are the areas
most prone to different Hb abnormalities and there
have been several studies for identification of these var-
iants in these regions [9]. Mazandaran is a province in
the north of Iran, by the Caspian Sea. The wide spec-
trum and high frequency of nondeletional a-globin
mutations in Mazandaran Province is remarkable and
seems to differ considerably from what has been found
in Mediterranean populations [9].
We have previously reported of less common Hb a-
chain mutations in that region, namely initiation codon
mutation (ATG > AGG, a2), J-Paris-I (GCC > GAC,
a1), codon 14 mutation (TGG > TAG, a1), codon 22
mutation (GGC > GGT, a2), Caserta (GCG > ACG,
a2), intervening sequence (IVS)-I-116 (A > G, a2), IVS-
II-55 (T > G, a2), Bleuland (ACC > AAC, a2), Sun
Prairie (GCT > CCT, a2), 3’UTR nt 46 (C > A, a2) [9],
J-Toronto (GCC > GAC, a1) and Setif (GAC > TAC,
a2) [10]. This short communication reports the first Hb
Q cases found in that region.
Besides Iran, there have been several reports of Hb-Q
from Turkey [3,6]. This is not the first hemoglobinopa-
t h yi nc o m m o nb e t w e e nI r a n i a na n dT u r k i s hp o p u l a -
tions. There are several findings of different abnormal
Hb molecules such as Hb J-Iran, Hb D-Iran, Hb Hama-
dan and Hb D-Punjab in people of both ethnicities [11].
Table 1 Hematologic indices and Hb electrophoresis of
our patients.
Proband Mother
Sex Male Female
Age (years) 22 38
Red blood cells (× 10
6/μL) 5.69 4.56
Hb (g/dL) 15.7 12.6
Hematocrit (%) 46.9 37.2
Mean corpuscular volume 82.4 81.7
MCH 27.7 27.6
MCH concentration (%) 33.6 33.8
Hb A (%) 78.2 78.3
Hb A2 (%) 2.1 2
Hb A2 variant (%) 0.5 0.5
Hb Q (%) 19.2 19.2
Hb: hemoglobin; MCH: Mean corpuscular hemoglobin
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may suggest a common ancestral origin for the people
in that region and help to propose immigration patterns
at the time of colonization by Aryans on the Iranian
Plateau and in Middle Asia, circa 4,000 BC.
Conclusion
Different hemoglobinopathies are frequently reported
from Northern Iran, but this is the first report of an Hb
Q-Iran mutation in members of a family from that
region. This report provides a substantial piece of evi-
dence in completing the list of discovered Hb abnormal-
ities on the southern shores of the Caspian Sea.
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